

## AMENDMENTS TO THE DRAWINGS

The attached sheet of drawings includes **Fig. 1** and replaces the original sheet of drawings that includes **Fig. 1**.

**Fig. 1** has been amended to expressly identify sequence with sequence identifier, *i.e.*, SEQ ID NO: 21. Applicants affirm that no new matter has been added by the newly submitted replacement **Fig. 1**.

Attachment: Replacement Sheet

## REMARKS/ARGUMENTS

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure dated August 22, 2011, the applicants respectfully request reconsideration in view of the following:

### Amendments to the Claims

Claims 1-21 are pending after entry of this paper. Claim 17 has been amended to correct a misspelling of the term “phosphoinositide.” No new matter has been added by this amendment.

### Amendments to the Specification

In the Notice to Comply, the Patent Office contends that the Sequence Listing is deficient because the specification lacks sequence identifiers that would expressly point to sequences listed in the submitted Sequence Listing. In order to expedite the prosecution of the present application, applicants respectfully amended specification to clearly mark sequences related to the sequences listed in the Sequence Listing.

In particular, (1) Table 1 has been amended to describe SEQ ID NOs (SEQ ID NOs: 1 and 21); (2) Table 2 has been amended to describe SEQ ID NOs (SEQ ID NOs: 23 to 25); (3) Paragraph [0044] of the present specification has been amended to describe SEQ ID NOs (SEQ ID NOs: 11 and 12); (4) Paragraph [0046] of the present specification has been amended to describe SEQ ID NOs (SEQ ID NOs: 13 to 19); (5) Paragraph [0058] of the present specification has been amended to describe a SEQ ID NO (SEQ ID NO: 1); (6) Paragraph [0060] of the present specification has been amended to describe a SEQ ID NO (SEQ ID NO: 1); (7) Paragraph [0061] of the present specification has been amended to describe SEQ ID NOs (SEQ ID NOs: 1 and 22); (8) Paragraph [0063] of the present specification has been amended to describe SEQ ID NOs (SEQ ID NOs: 20 and 1); and (9) Paragraph [0067] of the present specification has been amended to describe a SEQ ID NO (SEQ ID NO: 1).

Furthermore, the specification has been amended to correct the spelling of the term “phosphoinositide.” No new matter has been added by these amendments.

### **Amendments to the Drawings**

The drawings submitted on December 14, 2004 did not expressly identify the sequence with a sequence identifier. In accordance with the request made by the Patent Office expressed in the Notice to Comply, applicants submit herewith replacement drawings, *i.e.*, **Fig. 1**, which expressly identifies the sequence as SEQ ID NO: 21 found in the sequence listing. Applicants affirm that no new matter has been added by the newly submitted replacement **Fig. 1**.

### **Amendments to the Sequence Listing**

#### **(1) Amendment of SEQ ID NO: 20**

Applicants respectfully submit that an error was identified in the description of the amino acid sequence of SEQ ID NO: 20 presented in the Sequence Listing as filed. The third to last amino acid has been wrongly described as “threonine (T: Thr),” which should actually be “tryptophan (W: Trp).” Support may be found throughout the specification as filed, for example, in paragraph [0063].

#### **(2) Addition of SEQ ID NOs: 21 to 25**

The full-length sequence of human TCL1 protein described in **Table 1** and **Fig. 1**, the control sequence (EKQHAWLPLTIE) described in paragraph [0061], and the sequences of three target peptides described in **Table 2** of the specification as filed were not provided in the Sequence Listing as filed. To remedy this deficiency and in order to expedite the prosecution of the instant application, applicants have added these sequences as SEQ ID NOs: 21 to 25 to the Sequence Listing.

Applicants submit herewith (1) a substitute computer readable form (CRF) copy of the sequence listing, (2) a substitute paper copy of the sequence listing, and (3) a statement that the content of the sequence listing information recorded in computer readable form is identical to the sequence listing information provided on paper.

**AUTHORIZATION**

The Commissioner is hereby authorized to charge any additional fees which may be required for consideration of this Amendment to Deposit Account No. **50-4827**, Order No. 1004331.036US.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition for an extension of time, the Commissioner is requested to grant a petition for that extension of time required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No.**50-4827**, Order No. 1004331.036US.

Respectfully submitted,  
LOCKE LORD LLP

Dated: October 24, 2011

By: /Serge Ilin-Schneider/  
Serge Ilin-Schneider, Ph.D.  
Registration No. 61,584

**Correspondence Address:**

Address Associated With Customer Number:  
85775

(212) 415-8600 Telephone  
(212) 303-2754 Facsimile